A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, Uchiyama Y, Takeuchi Y, Okazawa M, Sakakibara H.
Totani Y, et al. Among authors: okazawa m.
Cancer Chemother Pharmacol. 2009 Nov;64(6):1181-5. doi: 10.1007/s00280-009-0981-1. Epub 2009 Apr 18.
Cancer Chemother Pharmacol. 2009.
PMID: 19377885
Clinical Trial.